Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib Plus Chemotherapy in Esophageal and Lung Squamous Cell Carcinoma
NCT03486509Phase 2Unknown
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Apr 2018
- Primary completion
- Mar 2020
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of afatinib in Esophageal Squamous Cell Carcinoma (ESCC), squamous cell carcinoma of the lung (LSCC), sponsored by Fujian Medical University Cancer Hospital. Status: unknown.
02
Drugs
afatinib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)squamous cell carcinoma of the lung (LSCC)
Beyond the preview
Go deeper on NCT03486509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03486509.